<DOC>
	<DOCNO>NCT01666509</DOCNO>
	<brief_summary>Rossoseq™ register treatment inflammatory skin condition . Rosacea one inflammatory skin disorder study yet use Rossoseq™ . Whilst rosacea show feature inflammatory skin disorder [ 1 ] , particularly stage 1 poorly understood treatment option limit therefore study - within target indication - contribute learn rosacea .</brief_summary>
	<brief_title>Efficacy Tolerability Topical Rossoseq™ Compared Vehicle Rosacea Subtype 1 ( Erythematotelangiectatic )</brief_title>
	<detailed_description>Male female subject ≥18 &lt; 85 year clinically diagnose rosacea subtype 1 ( erythematotelangiectatic ) define score 6-15 primary secondary feature rosacea standard grading system ( RSGS ; Wilkin et al , 2004 ) enrol . The study consist Screening visit , Baseline visit ( Week 0 ) , telephone call Week 1 , visit Week 2 4 , follow-up telephone call Week 5 . Eligible subject may may use medication rosacea time screen . Subjects concomitant use rosacea treatment take current medication return Baseline Visit end wash-out period . Eligible subject stratify gender ratio 4:1 ( Female : Male ) . Within stratum , subject randomise Baseline 2:1 ratio favour Rossoseq™ receive either Rossoseq™ vehicle . Efficacy evaluate use subject rating rosacea specific quality life instrument ( R-QOL ; Nicholson et al , 2007 ) office visit apply phone week 1 follow-up telephone call Week 5 . An investigator rating perform use `` 0=absent '' `` 3=severe '' grade RSGS primary feature flush , nontransient erythema , papule pustule , telangiectasia secondary feature burn stinging , plaque , dry appearance , edema , ocular manifestation phymatous change office visit . Ocular manifestation phymatous change need absent eligible study . Photographs document treatment effect take screening , baseline , week 2 week 4 .</detailed_description>
	<mesh_term>Rosacea</mesh_term>
	<criteria>Signed date informed consent prior studymandated procedure Clinically diagnose rosacea define score ≥6 ≤15 maximum score 30 primary secondary feature RSGS Female subject childbearing potential must use appropriate birth control Main exclusion Criteria : Pregnancy lactation Women follow menopausal symptom within last two year prior screen : excessive sweating , flushing , mood change Ocular manifestation rosacea Peripheral location ( ) rosacea Phymatous change Severe facial skin dryness xerosis Keratoconjunctivitis sicca Flushing due condition rosacea Any abnormal facial skin condition , e.g. , eczema , perioral dermatitis , broken bleeding skin area application Malignancy within past 2 year exception situ removal basal cell carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>